(Q38563530)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

estrogen-receptor positive breast cancer

21 February 2020

main subject

0 references

author

Delphine Mérino

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Geoffrey J. Lindeman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

S W Lok

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J E Visvader

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

10 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1877-1887

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2015.287

21 February 2020

exact match

0 references

cites work

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The genomic landscape of breast cancer as a therapeutic roadmap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Decoding and unlocking the BCL-2 dependency of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Many players in BCL-2 family affairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Cross-talk in cell death signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Low expression of bcl-2 in Brca1-associated breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Apoptosis in breast cancer: relationship with other pathological parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Targeting BCL2 for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Programmed anuclear cell death delimits platelet life span.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Structure-guided design of a selective BCL-X(L) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Patient-derived xenograft models of breast cancer and their predictive power

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Inhibitors of diverse metabolic steps cause increased apoptosis in deoxyadenosine-resistant mouse leukemia L1210 cells that lack p53 expression: convergence at caspase-3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Conditional deletion of the bcl-x gene from mouse mammary epithelium results in accelerated apoptosis during involution but does not compromise cell function during lactation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Forced involution of the functionally differentiated mammary gland by overexpression of the pro-apoptotic protein bax

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic influence of BCL2 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Analysis of the potent prognostic factors in luminal-type breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic value of bcl-2 expression among women with breast cancer in Libya

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.287

Paradoxical inhibition of solid tumor cell growth by bcl2

31 March 2020

1 reference

12 December 2020

Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis.

1 reference

12 December 2020

Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly

1 reference

12 December 2020

CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours

1 reference

12 December 2020

Apoptosis: an early event in metastatic inefficiency

1 reference

12 December 2020

Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line

1 reference

12 December 2020

Bcl-2 protein expression and long-term survival in breast cancer

1 reference

12 December 2020

Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2015.287

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26257067%20AND%20SRC:MED&resulttype=core&format=json